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Introduction: The beneﬁt of surfactant prescription for respiratory distress syndrome (RDS) has been
approved. Curosurf and Survanta are two commonly used natural surfactants in Iran. Previous studies did
not report priority for one of these two drugs. The present study aimed to compare the effectiveness and
safety of Curosurf and Survanta in treatment of RDS.
Methods: In this randomized clinical trial, neonates were born with RDS diagnosis in two governmental
and referral hospitals of Tehran (the capital of Iran) in 2014 were randomly selected. Neonates were
randomly assigned into two groups receiving 100 mg/kg Curosurf or Survanta as soon as possible after
randomization. Complications, mortality and needing the second dose were compared between the two
groups.
Results: A total 112 patients with the mean gestational age of 32.59 ± 3.39 weeks were evaluated (56
patients in each group). There were no signiﬁcant differences regarding birth weight, gestational age,
delivery method, and parity between the two groups (P > 0.05). The complications were occurred in 18
neonates (32.1%) of Curosurf group and 20 neonates (35.7%) of Survanta group (RR ¼ 0.922, 95%
CI ¼ 0.617e1.379). There were no signiﬁcant differences regarding complications, mortality, and needing
nasal CPAP and endotracheal tube between the two groups. In the neonates with gestational age of 29
e32 weeks the IVH and NEC incidence were signiﬁcantly more in Curosurf group compared to Survanta
group (27.8% vs 0% and 22.3% vs 0%, P < 0.05).
Conclusion: There was no signiﬁcant difference in complications or mortality between those two groups;
however Curosurf was associated with less need of ET tube (in >32 birth weeks subgroup) and NCPAP (in
29e32 birth weeks subgroup) (p ¼ 0.008). Further evaluations with longer follow-up duration are
needed for comparing these two surfactants.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Involving approximately 60% of infants with gestational age of
lower than 30 weeks and 42% of those with birthweight lower than
1500 gr, respiratory distress syndrome (RDS) or hyaline membrane
disease (HMD) is the most common respiratory disease and most
important cause of mortality in premature infants [1,2].hrati).
Inc. This is an open access article uRDS has a progressive trend and its severity increases during the
ﬁrst two days of life which may be resulted in death due to hyp-
oxemia and respiratory failure [3]. Various studies were conducted
to determine the physiopathology of the disease and eventually the
effect of surfactant in lung maturity was discovered in 1929. Suc-
cessful application of surfactant in RDS was ﬁrst reported in 1980
[4,5].
Respiratory protection, endotracheal mechanical ventilation
(EMV) and nasal continuous positive air way pressure (N.CPAP) and
surfactant prescription is the basis of management in RDS [6,7].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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design of new strategies [7]. Early application of N.CPAP and Sur-
factant has been shown effective in reducing need to EMV and
complications as well as improving RDS prognosis in infants [7,8].
Previous studies have reported INSURE as an effective method for
reducing side effects of RDS management as well as hospitalization
duration and expenses [9e11].
Thus the beneﬁt of surfactant prescription for RDS treatment has
been approved. At the present time, surfactant is available in Iran
with various trading names and there are some controversies about
their effectiveness. Curosurf and Survanta are two commonly used
natural surfactants in Iran. Previous studies did not show signiﬁ-
cant priority for one of these two drugs. So in the present study we
aimed to compare the effectiveness and safety of Curosurf versus
Survanta in treatment of RDS.
2. Methods
This randomized clinical trial was approved by ethics committee
of Baqiyatallah University of Medical Sciences (IR.BM-
SU.REC.1394.107) and was registered at Iranian Registry of Clinical
Trials (IRCT) with unique ID of IRCT2015082817413N12.
Neonates were born with RDS diagnosis in Najmieh and
Baqiyatallah hospitals, two governmental and referral hospitals
from south and north areas of Tehran (the capital of Iran) in 2014
were randomly selected. The selection was done based on a
randomization list among RDS neonates in 2014. Other inclusion
criteria were birth weight more than 750 gr; gestational age less
than 35 weeks; O2 saturation 85%e96%; signed informed consent
by parents, and age 6 h at the time of randomization. RDS diag-
nosis was based on clinical picture of infant with the onset of
progressive respiratory failure shortly after birth (manifested by an
increase in the work of breathing and an increase in the oxygen
requirement), in conjunctionwith a characteristic chest radiograph
(low lung volume and the classic diffuse reticulogranular ground-
glass appearance with air bronchograms).
Neonates with congenital heart diseases and other life threat-
ening congenital anomalies, respiratory failure due to other causes
except RDS, 5 min Apgar score 3, proven fetal lung maturity
proﬁle from amniocentesis, prior treatment with exogenous sur-
factant, prolonged (3 weeks) rupture of membranes, untreated
hypotension, or hypoglycemia, use of high-frequency ventilation
prior to ﬁrst dose of surfactant, and severe grades of intra-
ventricular hemorrhage (grades III or IV) by cranial ultrasound
prior to surfactant were excluded from study. The study ﬂowchart
is shown in Fig. 1.
Neonates were randomly assigned into two groups. Randomi-
zation was stratiﬁed by birth weight with two birth weight strata
(below 1250 gr and more than 1250 gr). A randomization list was
generated from 1 to 112 by SPSS software and neonates were
randomly assigned into each intervention group by their numbers.
The block randomization technique with 1:1 ratio was used to
achieve balanced group sizes.
2.1. Intervention
After intubation the group one infants were received 100 mg/kg
Curosurf and group two infants were received 100 mg/kg Survanta
as soon as possible after randomization. Infants were extubated
after surfactant injection and nasal continuous positive airway
pressure (CPAP) set at 4 cm H2O pressure. The nasal CPAP were
discontinued if the symptoms resolve and in case of FIO2 < 0e40,
PEEP <5 cm H2O, and in the arterial blood gases PaCO2 < 60 mmHg,
PaO2 > 50 mmHg, and PH > 7.25. In case of oxygen saturation by
pulse oximetry less than 85%, PaCO2 > 60mmHg, PaO2 < 50mmHg,and PH < 7.2 the PEEP was increased to 6 cm H2O and in case of
resistant oxygen saturation less than 85% the intubation was done
and continued by mechanical ventilation. Additional dose of sur-
factant was given in 12e24 h if the infant continued to require
mechanical ventilation and an FIO2 of 0.30 or greater tomaintain an
oxygen saturation by pulse oximetry greater than 85%.
2.2. Evaluations and measurements
Gestational age was measured by mean of two ﬁrst trimester
Crown Rump Length measurements at the ﬁrst antenatal visit.
The Apgar score was calculated using heart rate, respiratory
effort, muscle tone, reﬂex irritability, and color given values of 0, 1,
or 2 [12]. The diagnosis of sepsis was based on positive blood cul-
ture and pneumonia was approved by chest radiography, seeing
bilateral alveolar densities with air bronvhograms or irregular
patchy inﬁltrates. Cranial ultrasonography was also used for diag-
nosis of intraventricular hemorrhage (IVH).
2.3. Statistical analysis
Data were analyzed by statistical package for social sciences
(SPSS) version 21 (SPSS Inc. Chicago, IL) for windows. Study infants
described usingmean descriptive statistics, standard deviation, and
frequency then two groups compared by independent sample t-test
or its nonparametric equivalent (Mann-Whitney, if indicated) for
quantitative variables, then Chi-square or Fisher exact (if indicated)
tests used for qualitative variables. The P-values that were less than
0.05 were considered statistically signiﬁcant.
3. Results
A total 112 patients with the mean gestational age of
32.59 ± 3.39 weeks and birth weight of 1911.3 ± 786.5 gr were
evaluated (56 patients in each group). There were no signiﬁcant
differences regarding birth weight, gestational age, delivery
method, and parity between the two groups (P > 0.05, Table 1). Also
there were no signiﬁcant differences in mother's diabetes, steroid
injection, IUGR, placental abruption, PROM, ﬁrst and 5 min Apgar,
and needing CPR between the two groups (P > 0.05, Table 1). The
mother's hypertension was signiﬁcantly more in Curosurf group in
comparison of Survanta group (16.1% vs. 3.6%, P ¼ 0.026). Mothers/
neonates-related risk factors are shown in Table 1.
Time of surfactant injection was 8.04 ± 10.6 h in Curosurf group
and 8.35 ± 9.76 h in Survanta group (P ¼ 0.874). There were also no
signiﬁcant difference in needing the second surfactant dose be-
tween the two groups (OR ¼ 2.179, 95% CI ¼ 0.90e5.28). The mean
hospital stay was 16.57 ± 11.43 days in Curosurf group and
15.36 ± 14.39 days in Survanta group (P ¼ 0.622, Table 2).
3.1. Complications
Thirty eight neonates were complicated, the complications were
occurred in 18 neonates (32.1%) of Curosurf group and 20 neonates
(35.7%) of Survanta group (RR ¼ 0.922, 95% CI ¼ 0.617e1.379).
The sepsis was occurred in 7 neonates, pneumonia 16 neonates,
IVH in 11 neonates, pulmonary hemorrhage in 9 neonates, NEC in 8
neonates, pneumothorax in 7 neonates, and ROP in 4 neonates.
There were no signiﬁcant differences regarding complications be-
tween the two groups (Table 3).
Twenty one patients had gestational age of below 28 weeks (6
neonates in Curosurf and 15 neonates in Survanta groups). There
were no signiﬁcant differences regarding complications between
the two groups in below 28 weeks neonates; sepsis (16.7% vs 26.7%,
P ¼ 0.672), pneumonia (16.7% vs 13.3%, P ¼ 0.844), IVH (16.7% vs
Fig. 1. Study ﬂowchart.
Table 1
Baseline characteristics and risk factors of neonates.a,b
Variables Curosurf (N ¼ 56) Survanta (N ¼ 56) P Value
Gender 0.338
Male 30 (53.6) 35 (62.5)
Female 26 (46.4) 21 (37.5)
Birth weight, gr 1945.61 ± 723.9 1856.98 ± 848.5 0.544
Gestational age, weeks 33.21 ± 3.01 31.96 ± 3.66 0.051
 32 weeks 24 (42.9) 34 (60.7) 0.059
> 32 weeks 32 (57.1) 22 (39.3)
Delivery method 0.801
C/S 46 (82.1) 47 (83.9)
NVD 10 (17.9) 9 (16.1)
Parity 0.534
Nulliparous 41 (73.2) 38 (67.9)
Multiparous 15 (26.8) 18 (32.1)
Mother's underlying diseases
Diabetes 2 (3.6) 1 (1.8) 0.558
Hypertension 9 (16.1) 2 (3.6) 0.026
Steroid injection 37 (66.1) 44 (78.6) 0.102
IUGR 3 (5.4) 1 (1.8) 0.309
Placental abruption 1 (1.8) 2 (3.6) 0.558
PROM 5 (8.9) 11 (19.6) 0.088
First minute Apgar 8.20 ± 1.09 7.80 ± 1.49 0.114
Five minute Apgar 9.29 ± 1.07 9.02 ± 1.10 0.196
CPR 2 (3.6) 5 (8.9) 0.242
a Abbreviations: cesarean section (C/S), normal vaginal delivery (NVD), intrauterine
growth retardation (IUGR), premature rupture of membrane (PROM), and cardio-
pulmonary resynchronization (CPR).
b Data are presented as number (%) or mean ± standard deviation.
Table 2
Comparison of the time of ﬁrst surfactant injection, needing second dose, and mean
hospital stays between the two groups.a
Variables Curosurf (N ¼ 56) Survanta (N ¼ 56) P Value
Time of ﬁrst surfactant 8.04 ± 10.6 8.35 ± 9.76 0.874
< 2 h 23 (41.1) 21 (37.5) 0.789
2e12 h 22 (39.3) 21 (37.5)
> 12 h 11 (19.6) 14 (25)
Needing second dose 10 (17.9) 18 (32.1) 0.081
Hospital stay, days 16.57 ± 11.43 15.36 ± 14.39 0.622
a Data are presented as number (%) or mean ± standard deviation.
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P ¼ 0.442), NEC (16.7% vs 20%, P ¼ 0.648), pneumothorax (16.7%, vs
20%, P ¼ 0.648), and ROP (16.7% vs 6.7%, P ¼ 0.481).
There was also no signiﬁcant difference for occurrence of total
complications in the neonates with gestational age of below 28
weeks (RR ¼ 1.0, 95% CI ¼ 0.238e4.198).
In the neonates with below 28 weeks gestational age the
needing nasal CPAP was signiﬁcantly more in Curosurf group
(RR ¼ 4.25, 95% CI ¼ 1.32e13.73) but there was no signiﬁcant dif-
ference in needing ET tube between the two groups (RR¼ 0.80, 95%
CI ¼ 0.196e3.27).
Thirty seven neonates had gestational age of 29e32 weeks (18
neonates in Curosurf and 19 neonates in Survanta groups). The IVH
and NEC incidence were signiﬁcantly more in Curosurf group
compared to Survanta group (27.8% vs 0% and 22.3% vs 0%, P < 0.05).
Table 3
Comparing the occurrence of complications between the two groups.a,b
Complications Curosurf (N ¼ 56) Survanta (N ¼ 56) RR (95% CI)
Sepsis 2 (3.6) 5 (8.9) 1.80 (0.550e5.89)
Pneumonia 5 (8.9) 11 (19.6) 1.70 (0.802e3.60)
IVH 7 (12.5) 4 (7.1) 0.762 (0.476e1.24)
Pulmonary hemorrhage 3 (5.4) 6 (10.7) 1.54 (0.601e3.96)
NEC 5 (8.9) 3 (5.4) 0.785 (0.443e1.39)
Pneumothorax 2 (3.6) 5 (8.9) 1.80 (0.550e5.89)
ROP 3 (5.4) 1 (1.8) 0.654 (0.360e1.19)
Total complications 0.922 (0.617e1.379)
With complication 18 (32.1) 20 (35.7)
Without complication 38 (67.9) 36 (64.3)
Mortality 2 (3.6) 6 (10.7) 2.08 (0.617e6.99)
Nasal CPAP 11 (19.6) 14 (25) 0.851 (0.523e1.38)
ET Tube 17 (30.4) 27 (48.2) 0.674 (0.440e1.03)
a Abbreviations: intra-ventricular hemorrhage (IVH), necrotizing enteric colitis (NEC), retinopathy of prematurity (ROP), continuous positive airway pressure (CPAP),
endotracheal (ET). b Data are presented as number (%).
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tween the two groups in 29e32 weeks neonates (sepsis: 5.6% vs
5.3%, pneumonia: 0% vs 10.5%, pulmonary hemorrhage: 11.1% vs
5.3%, pneumothorax: 5.6% vs 5.3%, and ROP: 5.6% vs 0%, P > 0.05).
There was also no signiﬁcant difference in occurrence of total
complications in the neonates with gestational age of 29e32 weeks
(RR ¼ 1.0, 95% CI ¼ 0.238e4.198).
In the neonates with 29e32 weeks gestational age, the needing
nasal CPAP was signiﬁcantly more in Survanta group (RR ¼ 2.50,
95% CI ¼ 1.61e3.88) but there was no signiﬁcant difference in
needing ET tube between the two groups (RR ¼ 1.69, 95%
CI ¼ 0.351e1.34).
In the neonates with below 32 weeks gestational age, there
were no signiﬁcant differences in occurrence of each complication,
total complications, mortality, and needing nasal CPAP and ET tube
between the two groups (P > 0.05, Table 4).Table 4
Comparing the occurrence of complications between the two groups separated by
gestational age less and more than 32 weeks.
Complications Curosurf Survanta P Value
Gestational age 32 weeks (N ¼ 58)
Number 24 34
Sepsis 2 (8.3) 5 (14.7) 0.381
Pneumonia 1 (4.2) 4 (11.8) 0.304
IVH 6 (25) 4 (11.8) 0.189
Pulmonary hemorrhage 3 (12.5) 6 (17.6) 0.594
NEC 5 (20.8) 3 (8.8) 0.179
Pneumothorax 2 (8.3) 4 (11.8) 0.514
ROP 2 (8.3) 1 (2.9) 0.370
Total complications
With complication 12 (50) 13 (38.2)
Without complication 12 (50) 21 (61.8)
Mortality 1 (4.2) 6 (17.6) 0.221
Nasal CPAP 3 (12.5) 8 (23.5) 0.291
ET Tube 14 (58.3) 18 (52.9) 0.446
Gestational age > 32 weeks (N ¼ 54)
Number 32 22
Sepsis 0 (0) 0 (0) e
Pneumonia 4 (12.5) 7 (31.8) 0.083
IVH 1 (3.1) 0 (0) 0.593
Pulmonary hemorrhage 0 (0) 0 (0) e
NEC 0 (0) 0 (0) e
Pneumothorax 0 (0) 1 (4.5) 0.407
ROP 1 (3.1) 0 (0) 0.593
Total complications
With complication 6 (18.8) 7 (31.8)
Without complication 26 (81.2) 15 (68.2)
Mortality 1 (3.1) 0 (0) 0.403
Nasal CPAP 8 (25) 6 (27.3) 0.547
ET Tube 3 (9.4) 9 (40.9) 0.008In the neonates with more than 32 weeks gestational age, there
were no signiﬁcant differences in occurrence of each complication,
total complications, mortality, and needing nasal CPAP between the
two groups (P > 0.05, Table 4), but needing ET tube was signiﬁ-
cantly more in Survanta Group (P ¼ 0.008).
The mean gestational age was 31.32 ± 3.85 weeks in compli-
cated neonates and 33.24 ± 2.96 weeks in neonates without com-
plications (P¼ 0.004). The mean birth weight was 1694.87 ± 800 gr
in complicated neonates and 2022.43 ± 761 gr in non-complicated
neonates (P ¼ 0.036).
The complicated neonates were 71.1% boy and 28.9% girl while
the non-complicated neonates were 51.4% boy and 48.6% girl
(OR ¼ 2.325, 95% CI ¼ 1.01e5.37).
4. Discussion
Despite proper randomization in our study, there were slight
differences in birth weight and gestational age showing superiority
of Curosurf group. Thus the subgroup analyses were done for
removing confounders' effect. We found that among complications,
intraventricular hemorrhage (IVH) and necrotizing enterocollitis
(NEC) are more frequent in Curosurf group in comparison with
Survanta in 29e32 week neonates, while there was no signiﬁcant
difference between two groups for occurrence of other complica-
tions. We also realized that lower birthweight and lower gesta-
tional age were associated with more complications in both
Curosurf and Survanta groups. Prescription of Curosurf was asso-
ciated with lower CPAP or endotracheal tube requirement.
Ramanathan et al., comparing the effectiveness of Curosurf and
Survanta, concluded that Curosurf group had signiﬁcantly lower
oxygen demand [13]. Conﬁrming the results of the present study,
Dizdar et al. have reported equal mortality rate and complications
for both Curosurf and Survanta in a clinical trial. They also
concluded lower oxygen demand in Curosurf group in ﬁrst three
days of treatment which is in agreement with the present study
[14]. In another similar study on 150 premature infants by Ghar-
ehbaghi et al., theymentioned a signiﬁcantly lower intubation days
in Curosurf group in comparison with Survanta group, while there
was no signiﬁcant difference between two groups for occurrence of
other complications such as pneumothorax, patent ductus arte-
riosus (PDA), IVH, bronchopulmonary dysplasia and mortality rate
[15].
Evaluating 52 premature infants with RDS, allocated to two
Curosurf and Survanta groups, Fujii et al. reported a lower oxygen
therapy demand in ﬁrst 72 h of treatment for Curosurf group.
Curosurf treatment was also associated with lower PDA and air leak
complication in comparison with Survanta, while two groups had
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In another clinical trial by Bozdag et al. they concluded that both
Curosurf and Survanta improved oxygenation in VLBW infants with
pulmonary hemorrhage but there was no difference for these two
drugs for effectiveness on BPD as well as mortality rate [17]. Terek
et al., comparing effectiveness of Curosurf and Survanta in preterm
infants with RDS, mentioned that improvement of perfusion index
(PI) was achieved earlier in Survanta group in comparison with
Curosurf group. They also reported that inﬂammatory or oxidative
stress was normalized earlier with Curosurf [18]. Eras et al.
concluded that Survanta and Curosurf have similar effects in neu-
rodevelopmental outcomes when used for treatment of RDS in
preterm infants. There was no signiﬁcant difference between two
groups for incidence of cerebral palsy in their study [19]. In a
retrospective cohort study, Paul et al. reported no superiority or
preferential use of neither Survanta nor Curosurf in treatment of
RDS in preterm infants [20].
Both Curosurf and Survanta vials are available in Iran and there
is no tendency for more prescription of one of these drugs among
Iranian physicians. These vials have the same price as 370$ in Iran
and both of them are under appropriate cover of insurance. Our
ﬁndings show that prescription of Survanta is more associated with
need to injection of additional dose of surfactant; so prescribing
Survanta may impose higher expenses to the healthcare system,
Further studies, comparing more surfactant types, with more
follow-up duration are suggested. One of our study limitations was
non-matched patients in the two groups, thus future studies could
evaluate a narrower age group of neonates.
5. Conclusion
Among complications, intraventricular hemorrhage and necro-
tizing enterocollitis were more frequent in Curosurf group in
comparisonwith Survanta but therewere no signiﬁcant differences
in occurrence of other complications between the two groups. Our
results showed a slight superiority in prescription of Survanta
compared to Curosurf due to lower complications; however Cur-
osurf was observed to have less need to second doses injection, ET
tube and NCPAP. Our study did not show a prominent difference
between the two groups. Further evaluations with more follow-up
duration are needed for comparing these two surfactants.
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